{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:11:23Z","timestamp":1770513083456,"version":"3.49.0"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[1992,1,6]],"date-time":"1992-01-06T00:00:00Z","timestamp":694656000000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The FASEB Journal"],"published-print":{"date-parts":[[1992,1]]},"abstract":"<jats:p>\n                    Microsomal 4\u2010hydroxylase of 1,2,3,4\u2010tetrahydroisoquinoline (TIQ), a possible candidate for causing Parkinson disease, was characterized by using rat hepatic microsomes and purified P450 isozymes. Kinetic analysis revealed that\n                    <jats:italic>K<\/jats:italic>\n                    <jats:sub>m<\/jats:sub>\n                    and\n                    <jats:italic>V<\/jats:italic>\n                    <jats:sub>max<\/jats:sub>\n                    values (mean \u00b1\n                    <jats:sc>se<\/jats:sc>\n                    ) for hepatic microsomal TIQ 4\u2010hydroxylase of male Wistar rats were 319.6 \u00b1 26.8\n                    <jats:italic>\u03bc<\/jats:italic>\n                    <jats:sc>m<\/jats:sc>\n                    and 12.13\n                    <jats:italic>\u00b1<\/jats:italic>\n                    1.43 pmol\u00b7min\n                    <jats:sup>\u20131<\/jats:sup>\n                    \u00b7mg\n                    <jats:sup>\u20131<\/jats:sup>\n                    protein, respectively. When TIQ 4\u2010hydroxylase activity was compared in Wistar (an animal model of extensive debrisoquine metabolizers) and Dark Agouti (an animal model of poor debrisoquine metabolizers) rats, significant strain (Wistar &gt; Dark Agouti) and sex (male &gt; female) differences were observed. The microsomal activity toward TIQ 4\u2010hydroxylation was increased by pretreatment of male Wistar rats with P448 inducers (\n                    <jats:italic>\u03b2<\/jats:italic>\n                    \u2010naphthoflavone and sudan I), but not with phenobarbital. Pretreatment with propranolol, an inhibitor of P450 isozymes belonging to the P450 IID gene subfamily, decreased TIQ 4\u2010hydroxylase activity. P450 BTL, a P450 isozyme belonging to the IID subfamily, showed TIQ 4\u2010hydroxylase activity of 64.1 pmol \u00b7 min\n                    <jats:sup>\u20131<\/jats:sup>\n                    \u00b7 nmol P450\n                    <jats:sup>\u20131<\/jats:sup>\n                    , which was 3.2\u2010fold that of microsomes (20.9 pmol \u00b7 min\n                    <jats:sup>\u20131<\/jats:sup>\n                    \u00b7 nmol P450\n                    <jats:sup>\u20131<\/jats:sup>\n                    ). Antibody (IgG) against this isozyme suppressed microsomal TIQ 4\u2010hydroxylase activity concentration\u2010dependently. A male\u2010specific P450 ml (P450IIC11) catalyzed this reaction to a much lesser extent (10.0 pmol\u00b7min\n                    <jats:sup>\u20131<\/jats:sup>\n                    \u00b7nmol P450\n                    <jats:sup>\u20131<\/jats:sup>\n                    ), and its antibody did not affect the microsomal activity. These results suggest that TIQ 4\u2010hydroxylation in hepatic microsomes are catalyzed predominantly by a P450 isozyme (or isozymes) belonging to the IID gene subfamily in non\u2010treated rats and its immunochemically related P450 isozyme (or isozymes), and that a P450 isozyme (or isozymes) belonging to the IA subfamily also participates in TIQ 4\u2010hydroxylation in rats pretreated with P448\u2010inducers.\u2014Suzuki, T.; Fujita, S.; Narimatsu, S.; Masubuchi, Y.; Tachibana, M.; Ohta, S.; Hirobe M. Cytochrome P450 isozymes catalyzing 4\u2010hydroxylation of parkinsonism\u2010related compound 1,2,3,4\u2010tetrahydroisoquinoline in rat liver microsomes.\n                    <jats:italic>FASEB J.<\/jats:italic>\n                    6: 771\u2010776; 1992.\n                  <\/jats:p>","DOI":"10.1096\/fasebj.6.2.1537468","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T08:40:14Z","timestamp":1516264814000},"page":"771-776","source":"Crossref","is-referenced-by-count":28,"title":["Cytochrome P450 isozymes catalyzing 4\u2010hydroxylation of parkinsonism\u2010related compound 1,2,3,4\u2010tetrahydroisoquinoline in rat liver microsomes"],"prefix":"10.1096","volume":"6","author":[{"given":"Tokuji","family":"Suzuki","sequence":"first","affiliation":[{"name":"Department of Biopharmaceutics Faculty of Pharmaceutical Sciences Chiba University 1\u201033, Yayoi\u2010cho Chiba 260 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Faculty of Pharmaceutical Sciences Chiba University 1\u201033, Yayoi\u2010cho Chiba 260 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shizuo","family":"Narimatsu","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Faculty of Pharmaceutical Sciences Chiba University 1\u201033, Yayoi\u2010cho Chiba 260 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Masubuchi","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Faculty of Pharmaceutical Sciences Chiba University 1\u201033, Yayoi\u2010cho Chiba 260 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Tachibana","sequence":"additional","affiliation":[{"name":"Department of Biopharmaceutics Faculty of Pharmaceutical Sciences Chiba University 1\u201033, Yayoi\u2010cho Chiba 260 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ohta","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences University of Tokyo 7\u20103\u20101, Hongo Tokyo 113 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Hirobe","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences University of Tokyo 7\u20103\u20101, Hongo Tokyo 113 Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[1992,1,6]]},"container-title":["The FASEB Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.6.2.1537468","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/pdf\/10.1096\/fasebj.6.2.1537468","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T15:26:54Z","timestamp":1761665214000},"score":1,"resource":{"primary":{"URL":"https:\/\/faseb.onlinelibrary.wiley.com\/doi\/10.1096\/fasebj.6.2.1537468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,1]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,1]]}},"alternative-id":["10.1096\/fasebj.6.2.1537468"],"URL":"https:\/\/doi.org\/10.1096\/fasebj.6.2.1537468","archive":["Portico"],"relation":{},"ISSN":["0892-6638","1530-6860"],"issn-type":[{"value":"0892-6638","type":"print"},{"value":"1530-6860","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,1]]}}}